Promising Clinical Trial Results Drive Buy Rating for Bicara Therapeutics
In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), ...
Stifel Nicolaus Sticks to Their Buy Rating for Bicara Therapeutics Inc. (BCAX)
In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report).
Investing3 天
Bicara reports positive Phase 1/1b trial results for cancer therapy
BOSTON - Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biotech company with a market capitalization of $631 million currently trading near its 52-week low of $11.61, has shared promising ...
证券之星3 天
HC Wainwright & Co.：维持Bicara Therapeutics(BCAX.US)评级
HC Wainwright & Co.：维持Bicara Therapeutics(BCAX.US)评级，由买入调整至买入评级, 目标价由42.00美元调整至45.00美元。 Bicara Therapeutics（BCAX.US）公司简介 ...
Investing5 天
Bicara Therapeutics Inc (BCAX)
Aaa Aa Aaaaaa 199.53 +29.61% ...